Gemcitabine, oxaliplatin and 5-fluorouracil (5-FU) are active in biliary tract cancer and have a potentially synergistic mode of action and non-overlapping toxicity. The objective of these trials was to determine response, survival and toxicity separately in patients with bile duct cancer (BDC) an...
One occurred before the first dose and was not a treatment emergent Table 1 Patient demographics (N ¼ 23) Characteristics Age Previous Numbers (years) chemotherapies Gender Male Female 11 12 Primary cancer Bile duct cancer Breast cancer Breast cancer Breast cancer Colon cancer Colon cancer ...
Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;(3):CD004064.PubMedGoogle Scholar 5. Lordick F, Shitara K, Janjigian YY. New agents on the horizon in gastric cancer. Ann Oncol. 2017;28(8):1767-1775.PubMedGoogle ScholarCrossref 6. National Comprehensive ...
FULL PAPER British Journal of Cancer (2014) 111, 2268–2274 | doi: 10.1038/bjc.2014.554 Keywords: eribulin mesylate (E7389); cisplatin; advanced solid tumours Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors M Koczywas*,1, ...